Publication: 218

Publication: 218

Subcutaneous interleukin-4 (IL-4) for relapsed and resistant non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group, NCCTG 91-78-51.

PubMed

DOI

Google Scholar

Citation:: Leuk Lymphoma vol 48 (7) 1290-8

Year:: 2007
Type:: Manuscript
Funding:: NCTN
Endpoint:: Primary
Analysis:: Primary
Data Sharing:: No-Data-Sharing
Status:: Presented/Published
Citation Status:: pub

Note:

Methodological:: No
Biospecimen:: No
SDC:: No
Book Volume:

Parents:: None
Children:: None

Program:: OGC
Primary Committee:: Lymphoma
Sec. Committees:

Pharmas:
Grants:: CA-15083, CA-25224, CA-35103, CA-35113, CA-35195, CA-35269, CA-35448, CA-37404, CA-52352, CA-60276, CA-63849

Corr. Author:
Authors:: David M Kurtz Loren K Tschetter Jacob B Allred Susan M Geyer Paul J Kurtin Wesley D Putnam Kendrith M Rowland Martin Wiesenfeld Gamini S Soori Richard C Tenglin Albert M Bernath Thomas E Witzig

Networks:

Study: NCCTG-91-78-51
Multiple Studies, or Legacy Studies in Alliance Study:
Phases:: 2

Keywords:: Adult, Aged, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Humans, Interleukin-4, Lymphoma, Non-Hodgkin, Male, Middle Aged, Recurrence, Salvage Therapy, Survival Analysis, Treatment Outcome